You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTramadol
Accession NumberDB00193  (APRD00028)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionA narcotic analgesic proposed for moderate to severe pain. It may be habituating. [PubChem] Tramadol is also prepared as a variable release capsules, marketed under the brand name ConZip. For example, a 150 mg capsule will contain 37.5 mg of the immediate release form and 112.5 mg of the extended release form.
Structure
Thumb
Synonyms
(+)-Tramadol
(+)-trans-2-(Dimethylaminomethyl)-1-(m-methoxyphenyl)cyclohexanol
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ConzipCapsule, extended release300 mg/1OralVertical Pharmaceuticals Inc.2011-08-31Not applicableUs
ConzipCapsule, extended release100 mg/1OralVertical Pharmaceuticals, LLC2011-08-31Not applicableUs
ConzipCapsule, extended release100 mg/1OralVertical Pharmaceuticals Inc.2011-08-31Not applicableUs
ConzipCapsule, extended release200 mg/1OralVertical Pharmaceuticals, LLC2011-08-31Not applicableUs
ConzipCapsule, extended release200 mg/1OralVertical Pharmaceuticals Inc.2011-08-31Not applicableUs
ConzipCapsule, extended release300 mg/1OralVertical Pharmaceuticals, LLC2011-08-31Not applicableUs
DurelaCapsule, extended release100 mgOralCipher Pharmaceuticals Inc2012-03-19Not applicableCanada
DurelaCapsule, extended release200 mgOralCipher Pharmaceuticals Inc2012-03-19Not applicableCanada
DurelaCapsule, extended release300 mgOralCipher Pharmaceuticals Inc2012-03-19Not applicableCanada
RaliviaTablet, extended release300 mgOralValeant Canada Lp Valeant Canada S.E.C.2007-10-25Not applicableCanada
RaliviaTablet, extended release100 mgOralValeant Canada Lp Valeant Canada S.E.C.2007-10-25Not applicableCanada
RaliviaTablet, extended release200 mgOralValeant Canada Lp Valeant Canada S.E.C.2007-10-25Not applicableCanada
RyzoltTablet, extended release100 mg/1OralStat Rx USA2008-12-30Not applicableUs
RyzoltTablet, extended release300 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-22Not applicableUs
RyzoltTablet, extended release300 mg/1OralStat Rx USA2008-12-30Not applicableUs
RyzoltTablet, extended release200 mg/1OralStat Rx USA2008-12-30Not applicableUs
Taro-tramadol ERTablet, extended release100 mgOralTaro Pharmaceuticals Inc2016-03-07Not applicableCanada
Taro-tramadol ERTablet, extended release200 mgOralTaro Pharmaceuticals Inc2016-05-27Not applicableCanada
Taro-tramadol ERTablet, extended release300 mgOralTaro Pharmaceuticals Inc2016-05-27Not applicableCanada
Tramadol HydrochlorideCapsule, extended release150 mg/1Oralbryant ranch prepack2012-03-14Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralA S Medication Solutions Llc2012-03-14Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralKLE 2, Inc.2012-03-142015-12-29Us
Tramadol HydrochlorideTablet, extended release100 mg/1OralPatriot Pharmaceuticals, LLC2006-01-16Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralA S Medication Solutions Llc2012-03-14Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralPreferred Pharmaceuticals Inc.2015-09-18Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralProficient Rx LP2012-03-14Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralUnit Dose Services2012-03-14Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralProficient Rx LP2015-07-01Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralPatriot Pharmaceuticals, LLC2006-01-16Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralLake Erie Medical DBA Quality Care Products LLC2012-03-14Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralAidarex Pharmaceuticals LLC2012-03-14Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralPreferred Pharmaceuticals, Inc.2012-07-172016-10-13Us
Tramadol HydrochlorideCapsule, extended release150 mg/1OralMedsource Pharmaceuticals2012-03-14Not applicableUs
Tramadol HydrochlorideCapsule, coated, extended release150 mg/1OralDIRECT RX2014-01-01Not applicableUs
Tramadol HydrochlorideTablet, extended release300 mg/1OralPatriot Pharmaceuticals, LLC2006-01-16Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralREMEDYREPACK INC.2013-05-08Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralSta3, Llc2015-07-01Not applicableUs
Tramadol HydrochlorideCapsule150 mg/1OralDIRECT RX2015-01-01Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralUnit Dose Services2015-07-01Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralH.J. Harkins Company, Inc.2012-03-14Not applicableUs
Tramadol Hydrochloride Extended-releaseCapsule200 mg/1OralTrigen Laboratories, LLC2015-06-22Not applicableUs
Tramadol Hydrochloride Extended-releaseCapsule300 mg/1OralTrigen Laboratories, LLC2015-06-22Not applicableUs
Tramadol Hydrochloride Extended-releaseCapsule100 mg/1OralTrigen Laboratories, LLC2015-06-22Not applicableUs
TriduralTablet, extended release200 mgOralPaladin Labs Inc2007-08-14Not applicableCanada
TriduralTablet, extended release300 mgOralPaladin Labs Inc2007-08-14Not applicableCanada
TriduralTablet, extended release100 mgOralPaladin Labs Inc2007-08-14Not applicableCanada
UltramTablet, coated50 mg/1OralLake Erie Medical DBA Quality Care Products LLC2012-03-20Not applicableUs
UltramTablet, coated50 mg/1OralPd Rx Pharmaceuticals, Inc.1995-03-03Not applicableUs
UltramTablet, coated50 mg/1OralJanssen Pharmaceuticals, Inc.1995-03-03Not applicableUs
UltramTablet50 mgOralJanssen Inc2010-06-28Not applicableCanada
UltramTablet, coated50 mg/1OralA S Medication Solutions Llc1995-03-03Not applicableUs
UltramTablet, coated50 mg/1OralA S Medication Solutions Llc1995-03-03Not applicableUs
Ultram ERTablet, extended release300 mg/1OralJanssen Pharmaceuticals, Inc.2005-10-01Not applicableUs
Ultram ERTablet, extended release300 mg/1OralRebel Distributors Corp2005-09-08Not applicableUs
Ultram ERTablet, extended release200 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-20Not applicableUs
Ultram ERTablet, extended release100 mg/1OralRebel Distributors Corp2005-09-08Not applicableUs
Ultram ERTablet, extended release100 mg/1OralJanssen Pharmaceuticals, Inc.2005-10-01Not applicableUs
Ultram ERTablet, extended release100 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-27Not applicableUs
Ultram ERTablet, extended release200 mg/1OralJanssen Pharmaceuticals, Inc.2005-10-01Not applicableUs
Ultram ERTablet, extended release200 mg/1OralRebel Distributors Corp2005-09-08Not applicableUs
Ultram ERTablet100 mg/1OralREMEDYREPACK INC.2012-03-012016-10-28Us
Ultram ERTablet, extended release300 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-27Not applicableUs
Zytram XLTablet, extended release300 mgOralPurdue Pharma2006-12-07Not applicableCanada
Zytram XLTablet, extended release400 mgOralPurdue Pharma2006-12-07Not applicableCanada
Zytram XLTablet, extended release150 mgOralPurdue Pharma2006-12-07Not applicableCanada
Zytram XLTablet, extended release75 mgOralPurdue Pharma2011-03-02Not applicableCanada
Zytram XLTablet, extended release200 mgOralPurdue Pharma2006-12-07Not applicableCanada
Zytram XLTablet, extended release100 mgOralPurdue Pharma2011-03-02Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-tramadolTablet50 mgOralApotex Inc2014-06-23Not applicableCanada
TramadolTablet50 mg/1OralAccord Healthcare, Inc.2013-10-01Not applicableUs
Tramadol ERTablet, extended release200 mg/1OralStat Rx USA2009-10-27Not applicableUs
Tramadol HydrchlorideTablet50 mg/1OralREMEDYREPACK INC.2011-09-282016-11-15Us
Tramadol HydrochlorideTablet50 mg/1OralA S Medication Solutions Llc2002-06-22Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralSun Pharmaceutical Industries, Inc.2002-06-22Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralAurobindo Pharma Limited2015-10-20Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralMc Kesson Contract Packaging2011-10-19Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralBlenheim Pharmacal, Inc.2010-04-07Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralPreferred Pharmaceuticals, Inc.2009-11-23Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralSTAT Rx USA LLC2009-11-23Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralRed Pharm Drug, Inc.2010-11-15Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-02-07Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralMylan Institutional Inc.2002-08-01Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralCardinal Health2010-03-01Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2013-12-02Not applicableUs
Tramadol HydrochlorideTablet, extended release300 mg/1OralLupin Pharmaceuticals, Inc.2014-08-18Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralTeva Pharmaceuticals USA Inc2002-06-20Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralNorthstar Rx LLC2016-04-06Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralAidarex Pharmaceuticals LLC2010-11-15Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralUnit Dose Services2002-06-22Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralSun Pharma Global FZE2011-12-12Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralMylan Pharmaceuticals Inc.2016-03-16Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralSun Pharma Global FZE2011-12-30Not applicableUs
Tramadol HydrochlorideTablet, extended release300 mg/1OralUnit Dose Services2011-09-21Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralPhysicians Total Care, Inc.2002-06-21Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralREMEDYREPACK INC.2015-04-02Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-06-01Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralA S Medication Solutions2010-11-15Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralPar Pharmaceutical Inc.2009-11-13Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralREMEDYREPACK INC.2013-05-072016-10-13Us
Tramadol HydrochlorideTablet, film coated50 mg/1OralCardinal Health2002-06-21Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralCadila Healthcare Limited2011-01-31Not applicableUs
Tramadol HydrochlorideTablet50 mg/50mgOralAlivio Medical Products, Llc2015-10-01Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralA S Medication Solutions Llc2002-06-22Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralApotex Corp.2002-07-10Not applicableUs
Tramadol HydrochlorideTablet, extended release300 mg/1OralAurobindo Pharma Limited2015-10-20Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralVirtus Pharmaceuticals LLC2014-02-20Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralSTAT Rx USA LLC2002-06-22Not applicableUs
Tramadol HydrochlorideTablet, extended release300 mg/1OralPreferred Pharmaceuticals, Inc.2014-10-06Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralPd Rx Pharmaceuticals, Inc.2010-11-15Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralLake Erie Medical DBA Quality Care Products LLC2015-05-22Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralA S Medication Solutions Llc2002-06-22Not applicableUs
Tramadol HydrochlorideTablet, extended release300 mg/1OralSun Pharma Global FZE2011-12-12Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralMed Health Pharma, LLC2011-01-01Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralCardinal Health2002-06-22Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralAltura Pharmaceuticals, Inc.2010-01-01Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralDispensing Solutions, Inc.2009-11-13Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralMylan Pharmaceuticals Inc.2002-06-21Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralMajor Pharmaceuticals2014-02-26Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralAidarex Pharmaceuticals LLC2002-06-22Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralPreferred Pharmaceuticals Inc.2016-08-22Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralApotheca, Inc2005-04-26Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralRebel Distributors Corp.2009-11-23Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralMylan Pharmaceuticals Inc.2016-03-16Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralSun Pharma Global FZE2011-12-30Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralProficient Rx LP2010-11-15Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralUnit Dose Services2011-12-30Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralPhysicians Total Care, Inc.2010-11-17Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralProficient Rx LP2011-12-12Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralLupin Pharmaceuticals, Inc.2011-09-262016-05-31Us
Tramadol HydrochlorideTablet, film coated50 mg/1OralAurobindo Pharma Limited2014-03-31Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralVirtus Pharmaceuticals2015-05-22Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralREMEDYREPACK INC.2015-12-10Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-06-01Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralA S Medication Solutions2011-12-12Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralPar Pharmaceutical Inc.2009-11-13Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralREMEDYREPACK INC.2013-05-132016-10-13Us
Tramadol HydrochlorideTablet, coated50 mg/1OralPd Rx Pharmaceuticals, Inc.2010-11-15Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralDIRECT RX2014-01-01Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralA S Medication Solutions Llc2002-06-22Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralA S Medication Solutions Llc2009-11-13Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralSt. Mary's Medical Park Pharmacy2014-10-06Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralDispensing Solutions, Inc.2002-06-22Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralLupin Pharmaceuticals, Inc.2011-09-262015-11-30Us
Tramadol HydrochlorideTablet, extended release200 mg/1OralPreferred Pharmaceuticals, Inc.2014-10-062016-12-07Us
Tramadol HydrochlorideTablet, coated50 mg/1OralAphena Pharma Solutions Tennessee, Llc2010-11-15Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralREMEDYREPACK INC.2011-12-05Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralMacleods Pharmaceuticals Limited2015-10-07Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralDIRECT RX2014-01-01Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralREMEDYREPACK INC.2010-11-172016-10-13Us
Tramadol HydrochlorideTablet50 mg/1OralCardinal Health2010-03-23Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralReady Meds2010-11-15Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralZydus Pharmaceuticals (USA) Inc.2011-01-31Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-06-21Not applicableUs
Tramadol HydrochlorideTablet50 mg/1Oralbryant ranch prepack2002-06-22Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralLupin Pharmaceuticals, Inc.2014-08-18Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralCitron Pharma LLC2014-03-31Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralRebel Distributors Corp.2009-11-13Not applicableUs
Tramadol HydrochlorideTablet, extended release300 mg/1OralMylan Pharmaceuticals Inc.2016-03-16Not applicableUs
Tramadol HydrochlorideTablet, extended release300 mg/1OralSun Pharma Global FZE2011-12-30Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralDIRECT RX2016-12-01Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralUnit Dose Services2010-11-15Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralCardinal Health2010-11-15Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralREMEDYREPACK INC.2014-01-092016-10-13Us
Tramadol HydrochlorideTablet, extended release200 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-12-12Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralAurobindo Pharma Limited2015-10-20Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralLife Line Home Care Services, Inc.2011-01-01Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralBlenheim Pharmacal, Inc.2010-08-13Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralAmerican Health Packaging2014-08-21Not applicableUs
Tramadol HydrochlorideTablet, extended release300 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-12-12Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralUnit Dose Services2015-05-22Not applicableUs
Tramadol HydrochlorideTablet, extended release300 mg/1OralPar Pharmaceutical Inc.2011-09-21Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralPreferred Pharmaceuticals, Inc.2015-04-15Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralMedsource Pharmaceuticals2014-02-14Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralLake Erie Medical DBA Quality Care Products LLC2009-11-23Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralA S Medication Solutions Llc2009-11-13Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralPhysicians Total Care, Inc.2010-03-08Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralDIRECT RX2014-01-01Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralContract Pharmacy Services Pa2010-02-26Not applicableUs
Tramadol HydrochlorideTablet, extended release300 mg/1OralLupin Pharmaceuticals, Inc.2011-09-262015-12-31Us
Tramadol HydrochlorideTablet50 mg/1OralNorthstar Rx LLC2011-02-16Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralREMEDYREPACK INC.2015-02-26Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralRx Change Co.2014-11-14Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralA S Medication Solutions2010-11-15Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralREMEDYREPACK INC.2013-06-042016-10-13Us
Tramadol HydrochlorideTablet, film coated50 mg/1OralCardinal Health2011-02-04Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralAmneal Pharmaceuticals of New York, LLC2010-11-15Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralKeltman Pharmaceuticals Inc.2009-06-30Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralMajor Pharmaceuticals2010-03-01Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralCardinal Health2010-11-15Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1Oralbryant ranch prepack2010-11-15Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralLupin Pharmaceuticals, Inc.2014-08-18Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralBiomes Pharmaceuticals LLC2016-02-25Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralRebel Distributors Corp.2009-11-13Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-11-15Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralSun Pharma Global FZE2011-12-12Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralPreferred Pharmaceuticals Inc.2015-09-22Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralUnit Dose Services2011-12-30Not applicableUs
Tramadol Hydrochloride ERTablet, extended release100 mg/1OralDIRECT RX2014-01-01Not applicableUs
Tramadol Hydrochloride Extended-releaseTablet, film coated, extended release100 mg/1OralPar Pharmaceutical, Inc.2012-06-27Not applicableUs
Tramadol Hydrochloride Extended-releaseTablet, film coated, extended release200 mg/1OralPar Pharmaceutical, Inc.2012-06-27Not applicableUs
Tramadol Hydrochloride Extended-releaseTablet, film coated, extended release300 mg/1OralPar Pharmaceutical, Inc.2012-06-27Not applicableUs
UltramTablet, coated50 mg/201OralNorthwind Pharmaceuticals2014-02-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SynaprynKitOralFusion Pharmaceuticals LLC2009-09-14Not applicableUs
International Brands
NameCompany
RybixNot Available
TramalGrünenthal GmbH
Brand mixtures
NameLabellerIngredients
Act Tramadol/acetActavis Pharma Company
Apo-tramadol/acetApotex Inc
Auro-tramadol/acetaminophenAuro Pharma Inc
Ipg-tramadol/acetMarcan Pharmaceuticals Inc
Jamp-acet-tramadolJamp Pharma Corporation
Lupin-tramadol/acetLupin Pharma Canada Limited
Mar-tramadol/acetMarcan Pharmaceuticals Inc
Mint-tramadol/acetMint Pharmaceuticals Inc
Mylan-tramadol/acetMylan Pharmaceuticals Ulc
Pat-tramadol/acetPatriot A Division Of Janssen Inc
PMS-tramadol-acetPharmascience Inc
Priva-tramadol/acetPharmapar Inc
Ran-tramadol/acetRanbaxy Pharmaceuticals Canada Inc.
Riva-tramadol/acetLaboratoire Riva Inc
Teva-tramadol/acetaminophenTeva Canada Limited
Theratramadol-90Physician Therapeutics Llc
TramacetJanssen Inc
Tramadal Hydrochloride and AcetaminophenREMEDYREPACK INC.
Tramadol / AcetaminophenSivem Pharmaceuticals Ulc
Tramadol AcetaminophenDIRECT RX
Tramadol HCl and AcetaminophenAscend Laboratories, LLC
Tramadol Hydrochloride and AcetaminophenMylan Pharmaceuticals Inc.
Tramadol-acetPro Doc Limitee
Tramadol/acetSanis Health Inc
TramapapLiving Well Pharmacy, Inc.
Tramaphen-odanOdan Laboratories Ltd
UltracetRebel Distributors Corp
Salts
Name/CASStructureProperties
Tramadol Hydrochloride
36282-47-0
Thumb
  • InChI Key: PPKXEPBICJTCRU-XMZRARIVSA-N
  • Monoisotopic Mass: 299.165206788
  • Average Mass: 299.836
DBSALT000181
Categories
UNII39J1LGJ30J
CAS number27203-92-5
WeightAverage: 263.3752
Monoisotopic: 263.188529049
Chemical FormulaC16H25NO2
InChI KeyTVYLLZQTGLZFBW-ZBFHGGJFSA-N
InChI
InChI=1S/C16H25NO2/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3/t14-,16+/m1/s1
IUPAC Name
(1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol
SMILES
COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C
Pharmacology
IndicationIndicated in the treatment of moderate to severe pain. Consider for those prone to constipation or respiratory depression. Tramadol is used to treat postoperative, dental, cancer, and acute musculosketetal pain and as an adjuvant to NSAID therapy in patients with osteoarthritis.
Structured Indications
PharmacodynamicsTramadol, a centrally-acting analgesic, exists as a racemic mixture of the trans isomer, with important differences in binding, activity, and metabolism associated with the two enantiomers. Although its mode of action is not completely understood, from animal tests, at least two complementary mechanisms appear applicable: binding of parent and M1 metabolite to μ-opioid receptors and weak inhibition of reuptake of norepinephrine and serotonin. Opioid activity is due to both low affinity binding of the parent compound and higher affinity binding of the O-demethylated metabolite M1 to μ-opioid receptors. In animal models, M1 is up to 6 times more potent than tramadol in producing analgesia and 200 times more potent in μ-opioid binding. Opiate antagonist naloxone only partially antagonized tramadol-induced analgesia.
Mechanism of actionTramadol and its O-desmethyl metabolite (M1) are selective, weak OP3-receptor agonists. Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. The analgesic properties of Tramadol can be attributed to norepinephrine and serotonin reuptake blockade in the CNS, which inhibits pain transmission in the spinal cord. The (+) enantiomer has higher affinity for the OP3 receptor and preferentially inhibits serotonin uptake and enhances serotonin release. The (-) enantiomer preferentially inhibits norepinephrine reuptake by stimulating alpha(2)-adrenergic receptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
Mu-type opioid receptorProteinyes
agonist
HumanP35372 details
Sodium-dependent noradrenaline transporterProteinyes
inhibitor
HumanP23975 details
Sodium-dependent serotonin transporterProteinyes
inhibitor
HumanP31645 details
5-hydroxytryptamine receptor 2CProteinunknown
antagonist
HumanP28335 details
Kappa-type opioid receptorProteinunknown
agonist
HumanP41145 details
Delta-type opioid receptorProteinno
agonist
HumanP41143 details
Glutamate receptor ionotropic, NMDA 3AProteinunknown
antagonist
HumanQ8TCU5 details
Alpha-7 nicotinic cholinergic receptor subunitProteinunknown
antagonist
HumanQ693P7 details
Muscarinic acetylcholine receptor M3Proteinunknown
antagonist
HumanP20309 details
Related Articles
AbsorptionRacemic tramadol is rapidly and almost completely absorbed after oral administration. The mean absolute bioavailability of a 100 mg oral dose is approximately 75%. The mean peak plasma concentration of racemic tramadol and M1 occurs at two and three hours, respectively, after administration in healthy adults.
Volume of distribution
  • 2.6 L/kg [male, 100 mg intravenous dose]
  • 2.9 L/kg [female, 100 mg intravenous dose]
Protein binding20% bound to plasma proteins.
Metabolism

Hepatic. The major metabolic pathways appear to be N- and O- demethylation and glucuronidation or sulfation in the liver. One metabolite (O-desmethyltramadol, denoted M1) is pharmacologically active in animal models. CYP3A4 and CYP2B6 facilitates the biotransformation of tramadol to N-desmethyl-tramadol. CYP2D6 facilitates the biotransformation of tramadol to O-desmethyl-tramadol.

SubstrateEnzymesProduct
Tramadol
O-DesmethyltramadolDetails
Tramadol
N-DesmethyltramadolDetails
O-Desmethyltramadol
O-Desmethyl-tramado glucuronideDetails
O-Desmethyltramadol
N,O-didesmethyltramadolDetails
N-Desmethyltramadol
N,O-didesmethyltramadolDetails
N-Desmethyltramadol
N,N-didesmethyltramadolDetails
N,O-didesmethyltramadol
Not Available
N,N,O-tridesmethyl-tramadolDetails
N,N-didesmethyltramadol
Not Available
N,N,O-tridesmethyl-tramadolDetails
Route of eliminationTramadol is eliminated primarily through metabolism by the liver and the metabolites are excreted primarily by the kidneys. Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% of the dose is excreted as metabolites.
Half lifeTramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.
Clearance
  • 5.9 mL/min/Kg [Healthy Adults, 100 mg qid, MD p.o]
  • 8.5 mL/min/Kg [Healthy Adults, 100 mg SD p.o]
  • 6.89 mL/min/Kg [Geriatric, (<75 yr), 50 mg SD p.o.]
  • 4.23 mL/min/Kg [Hepatic Impaired, 50 mg SD p.o.]
  • 4.23 mL/min/Kg [Renal Impaired, Clcr10-3mL/min, 100 mg SD i.v.]
  • 3.73 mL/min/Kg [Renal Impaired, CLcr<5 mL/min, 100 mg SD i.v.]
  • 6.4 mL/min/Kg [Male following a 100 mg IV dose]
  • 5.7 mL/min/Kg [Female following a 100 mg IV dose]
ToxicityLD50=350mg/kg (orally in mice)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Tramadol Metabolism PathwayDrug metabolismSMP00637
Tramadol Action Action PathwayDrug actionSMP00671
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Tramadol is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Tramadol.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Tramadol.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Tramadol.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Tramadol.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Tramadol is combined with 7-Nitroindazole.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINETramadol may increase the neuroexcitatory activities of 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AbirateroneThe serum concentration of Tramadol can be increased when it is combined with Abiraterone.Approved
AcenocoumarolTramadol may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Tramadol is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Acetophenazine.Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Tramadol.Approved
adipiplonThe risk or severity of adverse effects can be increased when Tramadol is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Tramadol is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Tramadol is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Tramadol is combined with Alfentanil.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Tramadol.Approved, Vet Approved
AlmotriptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Almotriptan.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Tramadol is combined with Alprazolam.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Tramadol is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Tramadol is combined with Amiloride.Approved
AmineptineAmineptine may increase the neuroexcitatory activities of Tramadol.Illicit, Withdrawn
AmiodaroneThe therapeutic efficacy of Tramadol can be decreased when used in combination with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Tramadol is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may increase the neuroexcitatory activities of Tramadol.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Tramadol which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Tramadol is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Tramadol is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Tramadol.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Tramadol.Approved
AprepitantThe serum concentration of Tramadol can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Tramadol is combined with Aripiprazole.Approved, Investigational
ArtemetherThe therapeutic efficacy of Tramadol can be decreased when used in combination with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Tramadol is combined with Asenapine.Approved
AtazanavirThe serum concentration of Tramadol can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Atomoxetine.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Tramadol.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Tramadol.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Azaperone.Vet Approved
AzelastineTramadol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Tramadol is combined with Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Tramadol is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Tramadol is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Barbital.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Tramadol.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Tramadol is combined with Bendroflumethiazide.Approved
BenmoxinTramadol may increase the neuroexcitatory activities of Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Tramadol is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Tramadol.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Tramadol.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Tramadol is combined with Benzyl alcohol.Approved
BetaxololThe therapeutic efficacy of Tramadol can be decreased when used in combination with Betaxolol.Approved
BexaroteneThe serum concentration of Tramadol can be decreased when it is combined with Bexarotene.Approved, Investigational
BifeprunoxThe risk or severity of adverse effects can be increased when Tramadol is combined with Bifeprunox.Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Tramadol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Tramadol.Investigational
BoceprevirThe serum concentration of Tramadol can be increased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Tramadol can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Tramadol can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Tramadol is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved
BromazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Bromazepam.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Tramadol is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Tramadol is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Tramadol is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Tramadol is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Tramadol is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Bupivacaine.Approved, Investigational
BuprenorphineTramadol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe therapeutic efficacy of Tramadol can be decreased when used in combination with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Tramadol is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Butabarbital.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Tramadol is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Tramadol is combined with Butethal.Approved, Illicit
ButorphanolButorphanol may decrease the analgesic activities of Tramadol.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cabergoline.Approved
Canrenoic acidThe risk or severity of adverse effects can be increased when Tramadol is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Canrenone.Investigational
CarbamazepineTramadol may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Tramadol is combined with Carfentanil.Illicit, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cariprazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Tramadol is combined with Carisoprodol.Approved
CaroxazoneTramadol may increase the neuroexcitatory activities of Caroxazone.Withdrawn
CelecoxibThe therapeutic efficacy of Tramadol can be decreased when used in combination with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Tramadol can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Tramadol is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Chloroprocaine.Approved
ChloroquineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Tramadol.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Tramadol.Illicit, Withdrawn
ChlorpromazineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorzoxazone.Approved
CholecalciferolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Cholecalciferol.Approved, Nutraceutical
CicletanineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cicletanine.Investigational
CimetidineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Cimetidine.Approved
CinacalcetThe therapeutic efficacy of Tramadol can be decreased when used in combination with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cinchocaine.Approved, Vet Approved
CitalopramCitalopram may increase the neuroexcitatory activities of Tramadol.Approved
ClarithromycinThe serum concentration of Tramadol can be increased when it is combined with Clarithromycin.Approved
ClemastineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Tramadol is combined with Clidinium.Approved
ClobazamThe therapeutic efficacy of Tramadol can be decreased when used in combination with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Tramadol is combined with clomethiazole.Investigational
ClomipramineClomipramine may increase the neuroexcitatory activities of Tramadol.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Clonidine.Approved
ClopidogrelThe metabolism of Tramadol can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Tramadol is combined with Clorazepate.Approved, Illicit
ClotrimazoleThe therapeutic efficacy of Tramadol can be decreased when used in combination with Clotrimazole.Approved, Vet Approved
ClozapineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Clozapine.Approved
CobicistatThe therapeutic efficacy of Tramadol can be decreased when used in combination with Cobicistat.Approved
CocaineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Tramadol is combined with Codeine.Approved, Illicit
ConivaptanThe serum concentration of Tramadol can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Tramadol can be decreased when combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may increase the neuroexcitatory activities of Tramadol.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Tramadol.Approved
CyclosporineThe metabolism of Tramadol can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Tramadol is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Tramadol can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Tramadol is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Tramadol is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Tramadol.Investigational
DarifenacinThe therapeutic efficacy of Tramadol can be decreased when used in combination with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Tramadol can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Tramadol can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Tramadol can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Tramadol is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Tramadol is combined with Desflurane.Approved
DesipramineDesipramine may increase the neuroexcitatory activities of Tramadol.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Tramadol is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Tramadol is combined with Desmopressin.Approved
DesvenlafaxineDesvenlafaxine may increase the neuroexcitatory activities of Tramadol.Approved
DetomidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Tramadol can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Tramadol is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Tramadol.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Tramadol.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Tramadol is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Tramadol is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Tramadol is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Tramadol is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Diazepam.Approved, Illicit, Vet Approved
DicoumarolTramadol may increase the anticoagulant activities of Dicoumarol.Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Tramadol.Approved
DiethylpropionDiethylpropion may increase the analgesic activities of Tramadol.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Tramadol is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Tramadol is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Tramadol is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Tramadol is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Tramadol can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Tramadol is combined with Dimenhydrinate.Approved
DiphenhydramineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Tramadol is combined with Diphenoxylate.Approved, Illicit
DolasetronDolasetron may decrease the analgesic activities of Tramadol.Approved
DoramectinThe risk or severity of adverse effects can be increased when Tramadol is combined with Doramectin.Vet Approved
DosulepinDosulepin may increase the neuroexcitatory activities of Tramadol.Approved
DoxepinDoxepin may increase the neuroexcitatory activities of Tramadol.Approved
DoxorubicinThe metabolism of Tramadol can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Tramadol can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Tramadol is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Illicit
DronedaroneThe therapeutic efficacy of Tramadol can be decreased when used in combination with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Tramadol is combined with Drotebanol.Experimental, Illicit
DuloxetineDuloxetine may increase the neuroexcitatory activities of Tramadol.Approved
DyclonineThe risk or severity of adverse effects can be increased when Tramadol is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Tramadol is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Tramadol is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Tramadol is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Tramadol can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Tramadol is combined with Efonidipine.Approved
EletriptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Eletriptan.Approved, Investigational
EliglustatThe therapeutic efficacy of Tramadol can be decreased when used in combination with Eliglustat.Approved
EluxadolineTramadol may increase the constipating activities of Eluxadoline.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Tramadol is combined with Enflurane.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Tramadol is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Tramadol can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Eplerenone.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Tramadol is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Tramadol is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Ergotamine.Approved
ErythromycinThe metabolism of Tramadol can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramEscitalopram may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Tramadol can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineEsmirtazapine may increase the neuroexcitatory activities of Tramadol.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Tramadol is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Tramadol is combined with Eszopiclone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Tramadol is combined with Etacrynic acid.Approved
EthanolTramadol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tramadol.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Tramadol.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateTramadol may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Tramadol is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Tramadol is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Tramadol is combined with Etomidate.Approved
EtoperidoneEtoperidone may increase the neuroexcitatory activities of Tramadol.Approved
EtorphineThe risk or severity of adverse effects can be increased when Tramadol is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Tramadol can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Tramadol is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Tramadol is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Tramadol is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tramadol.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Tramadol is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Tramadol is combined with Flibanserin.Approved
FluconazoleThe metabolism of Tramadol can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Fludiazepam.Approved, Illicit
FluindioneTramadol may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Tramadol is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Flunitrazepam.Approved, Illicit
FluoxetineFluoxetine may increase the neuroexcitatory activities of Tramadol.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Tramadol is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Tramadol is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Tramadol is combined with Fluticasone Propionate.Approved
FluvoxamineFluvoxamine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
FosamprenavirThe metabolism of Tramadol can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Tramadol can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Tramadol can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Tramadol is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Frovatriptan.Approved, Investigational
FurazolidoneTramadol may increase the neuroexcitatory activities of Furazolidone.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Tramadol is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Tramadol can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Tramadol is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Tramadol is combined with gabapentin enacarbil.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Tramadol.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Tramadol is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Tramadol is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Tramadol is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Tramadol.Approved, Investigational, Vet Approved
GranisetronGranisetron may decrease the analgesic activities of Tramadol.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Tramadol is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Tramadol is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Tramadol is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Tramadol.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Tramadol.Approved
HydracarbazineTramadol may increase the neuroexcitatory activities of Hydracarbazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Tramadol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneTramadol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Tramadol is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Hydromorphone.Approved, Illicit
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Tramadol.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Tramadol.Approved
IdelalisibThe serum concentration of Tramadol can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Iloperidone.Approved
ImatinibThe metabolism of Tramadol can be decreased when combined with Imatinib.Approved
ImipramineImipramine may increase the neuroexcitatory activities of Tramadol.Approved
IndalpineIndalpine may increase the neuroexcitatory activities of Tramadol.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Tramadol is combined with Indapamide.Approved
IndinavirThe therapeutic efficacy of Tramadol can be decreased when used in combination with Indinavir.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tramadol.Approved
IproclozideTramadol may increase the neuroexcitatory activities of Iproclozide.Withdrawn
IproniazidTramadol may increase the neuroexcitatory activities of Iproniazid.Withdrawn
IsavuconazoniumThe metabolism of Tramadol can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidTramadol may increase the neuroexcitatory activities of Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Tramadol is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe therapeutic efficacy of Tramadol can be decreased when used in combination with Isoniazid.Approved
IsosorbideThe risk or severity of adverse effects can be increased when Tramadol is combined with Isosorbide.Approved
IsradipineThe metabolism of Tramadol can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Tramadol can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Tramadol can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Tramadol is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Ketobemidone.Approved
KetoconazoleThe therapeutic efficacy of Tramadol can be decreased when used in combination with Ketoconazole.Approved, Investigational
KW-3902The risk or severity of adverse effects can be increased when Tramadol is combined with KW-3902.Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Tramadol is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Tramadol is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Tramadol is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Tramadol is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Tramadol is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Tramadol is combined with Levomethadyl Acetate.Approved
LevomilnacipranLevomilnacipran may increase the neuroexcitatory activities of Tramadol.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Tramadol is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Lidocaine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Tramadol is combined with Linezolid.Approved, Investigational
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Tramadol.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Tramadol is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Tramadol is combined with Lofentanil.Illicit
LopinavirThe serum concentration of Tramadol can be increased when it is combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Tramadol is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tramadol.Approved
LorcaserinThe therapeutic efficacy of Tramadol can be decreased when used in combination with Lorcaserin.Approved
LovastatinThe metabolism of Tramadol can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Tramadol is combined with Loxapine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Tramadol is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Tramadol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Tramadol can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Tramadol is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Tramadol is combined with Maprotiline.Approved
MebanazineTramadol may increase the neuroexcitatory activities of Mebanazine.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tramadol.Approved
MeclizineThe risk or severity of adverse effects can be increased when Tramadol is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Tramadol is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Melperone.Approved
MephedroneMephedrone may increase the analgesic activities of Tramadol.Investigational
MephentermineMephentermine may increase the analgesic activities of Tramadol.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Tramadol is combined with Meprobamate.Approved, Illicit
MersalylThe risk or severity of adverse effects can be increased when Tramadol is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Tramadol is combined with Metaxalone.Approved
MethadoneThe therapeutic efficacy of Tramadol can be decreased when used in combination with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Tramadol is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Tramadol.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Tramadol.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Tramadol is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Tramadol is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Methohexital.Approved
MethotrimeprazineTramadol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Tramadol is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Tramadol is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Tramadol is combined with Methyclothiazide.Approved
Methylene blueTramadol may increase the neuroexcitatory activities of Methylene blue.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Methylphenobarbital.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Tramadol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Tramadol is combined with Metoclopramide.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Tramadol.Approved, Investigational
MetyrosineTramadol may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Tramadol is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Tramadol can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the neuroexcitatory activities of Tramadol.Approved
MinaprineTramadol may increase the neuroexcitatory activities of Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Investigational
MirabegronThe therapeutic efficacy of Tramadol can be decreased when used in combination with Mirabegron.Approved
MirtazapineMirtazapine may increase the neuroexcitatory activities of Tramadol.Approved
MitotaneThe serum concentration of Tramadol can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may increase the analgesic activities of Tramadol.Experimental, Illicit
MoclobemideTramadol may increase the neuroexcitatory activities of Moclobemide.Approved
ModafinilThe serum concentration of Tramadol can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Tramadol.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Tramadol is combined with Morphine.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Tramadol.Vet Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Investigational
NafcillinThe serum concentration of Tramadol can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may decrease the analgesic activities of Tramadol.Approved
NaltrexoneThe therapeutic efficacy of Tramadol can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Naratriptan.Approved, Investigational
NefazodoneNefazodone may increase the neuroexcitatory activities of Tramadol.Approved, Withdrawn
NelfinavirThe serum concentration of Tramadol can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Tramadol can be increased when it is combined with Netupitant.Approved
NevirapineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Nevirapine.Approved
NialamideTramadol may increase the neuroexcitatory activities of Nialamide.Withdrawn
NicardipineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Nicardipine.Approved
NilotinibThe therapeutic efficacy of Tramadol can be decreased when used in combination with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Tramadol is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the neuroexcitatory activities of Tramadol.Approved
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Tramadol.Investigational
OctamoxinTramadol may increase the neuroexcitatory activities of Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Tramadol is combined with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Tramadol can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Tramadol is combined with Olopatadine.Approved
OndansetronOndansetron may decrease the analgesic activities of Tramadol.Approved
OpipramolOpipramol may increase the neuroexcitatory activities of Tramadol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Tramadol is combined with Opium.Approved, Illicit
OrphenadrineTramadol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Tramadol is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Tramadol can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxybuprocaine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Tramadol.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Tramadol.Approved
PalbociclibThe serum concentration of Tramadol can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Paliperidone.Approved
PalonosetronPalonosetron may decrease the analgesic activities of Tramadol.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Tramadol.Approved
PanobinostatThe serum concentration of Tramadol can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeTramadol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineTramadol may increase the neuroexcitatory activities of Pargyline.Approved
ParoxetineParoxetine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Tramadol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Tramadol.Approved
PentazocinePentazocine may decrease the analgesic activities of Tramadol.Approved, Vet Approved
PentobarbitalThe metabolism of Tramadol can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Tramadol.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved
PerazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Tramadol is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Pethidine.Approved
PhenelzineTramadol may increase the neuroexcitatory activities of Phenelzine.Approved
PhenindioneTramadol may increase the anticoagulant activities of Phenindione.Approved
PheniprazineTramadol may increase the neuroexcitatory activities of Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Tramadol can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Tramadol is combined with Phenoxyethanol.Approved
PhenoxypropazineTramadol may increase the neuroexcitatory activities of Phenoxypropazine.Withdrawn
PhenprocoumonTramadol may increase the anticoagulant activities of Phenprocoumon.Approved
PhenterminePhentermine may increase the analgesic activities of Tramadol.Approved, Illicit
PhenytoinThe metabolism of Tramadol can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Tramadol is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Pipamperone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Tramadol.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Tramadol.Approved
PiretanideThe risk or severity of adverse effects can be increased when Tramadol is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Tramadol is combined with Piritramide.Investigational
PirlindoleTramadol may increase the neuroexcitatory activities of Pirlindole.Approved
PivhydrazineTramadol may increase the neuroexcitatory activities of Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Tramadol is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Tramadol is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Tramadol is combined with Pomalidomide.Approved
PosaconazoleThe serum concentration of Tramadol can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PotassiumThe risk or severity of adverse effects can be increased when Tramadol is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Tramadol is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleTramadol may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Tramadol is combined with Pregabalin.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Tramadol is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Prilocaine.Approved
PrimidoneThe metabolism of Tramadol can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Procarbazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Prochlorperazine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Tramadol.Approved
PromazineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Promethazine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Tramadol.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Proparacaine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Propericiazine.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Tramadol.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Tramadol.Investigational
PropofolThe risk or severity of adverse effects can be increased when Tramadol is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Propoxycaine.Approved
ProthipendylThe risk or severity of adverse effects can be increased when Tramadol is combined with Prothipendyl.Investigational
ProtriptylineProtriptyline may increase the neuroexcitatory activities of Tramadol.Approved
PSD502The risk or severity of adverse effects can be increased when Tramadol is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Tramadol.Approved
QuazepamThe serum concentration of Tramadol can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Tramadol is combined with Quetiapine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Quinethazone.Approved
QuinidineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Quinidine.Approved
QuinineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Tramadol is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Tramadol is combined with Ramelteon.Approved, Investigational
RamosetronTramadol may increase the constipating activities of Ramosetron.Approved
RanolazineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Ranolazine.Approved, Investigational
RasagilineTramadol may increase the neuroexcitatory activities of Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Tramadol is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Tramadol is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Tramadol is combined with Reserpine.Approved
RifabutinThe metabolism of Tramadol can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Tramadol can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Tramadol can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Tramadol is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Tramadol.Investigational
RitonavirThe serum concentration of Tramadol can be increased when it is combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Rizatriptan.Approved
RolapitantThe therapeutic efficacy of Tramadol can be decreased when used in combination with Rolapitant.Approved
RolofyllineThe risk or severity of adverse effects can be increased when Tramadol is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Romifidine.Vet Approved
RopiniroleThe therapeutic efficacy of Tramadol can be decreased when used in combination with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Ropivacaine.Approved
RotigotineTramadol may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Tramadol.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Tramadol is combined with S-Ethylisothiourea.Experimental
SafrazineTramadol may increase the neuroexcitatory activities of Safrazine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Tramadol is combined with Sage 547.Investigational
SaquinavirThe serum concentration of Tramadol can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Tramadol.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Secobarbital.Approved, Vet Approved
SelegilineTramadol may increase the neuroexcitatory activities of Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Tramadol is combined with Sertindole.Approved, Withdrawn
SertralineSertraline may increase the neuroexcitatory activities of Tramadol.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Tramadol is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Tramadol can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Tramadol can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Tramadol can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Tramadol.Approved
SorafenibThe metabolism of Tramadol can be decreased when combined with Sorafenib.Approved, Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Tramadol can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StiripentolThe serum concentration of Tramadol can be increased when it is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Tramadol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Tramadol is combined with Sufentanil.Approved, Investigational
SulfisoxazoleThe metabolism of Tramadol can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Tramadol is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Sumatriptan.Approved, Investigational
SuvorexantTramadol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tramadol is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tramadol is combined with Tasimelteon.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Tramadol.Approved
TelaprevirThe serum concentration of Tramadol can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Tramadol can be increased when it is combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Temazepam.Approved
TerbinafineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Terbinafine.Approved, Investigational, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tramadol is combined with Tetrodotoxin.Investigational
ThalidomideTramadol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Tramadol is combined with Theobromine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Tramadol is combined with Thiamylal.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Tramadol.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Tramadol is combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Tramadol.Approved
ThiotepaThe metabolism of Tramadol can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Tramadol is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tramadol is combined with Tiagabine.Approved
TianeptineTianeptine may increase the neuroexcitatory activities of Tramadol.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tramadol is combined with Tiapride.Investigational
TiclopidineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Ticlopidine.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Tramadol is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Tiletamine.Vet Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Tramadol.Approved
TipranavirThe therapeutic efficacy of Tramadol can be decreased when used in combination with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Tramadol can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tramadol is combined with Tolcapone.Approved, Withdrawn
ToloxatoneTramadol may increase the neuroexcitatory activities of Toloxatone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Tramadol.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Tramadol is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Tramadol is combined with Torasemide.Approved
Trans-2-PhenylcyclopropylamineTramadol may increase the neuroexcitatory activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineTramadol may increase the neuroexcitatory activities of Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Trazodone.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Tramadol is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Tramadol is combined with Triazolam.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Tramadol is combined with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Tramadol.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Tramadol.Approved
TrimipramineTrimipramine may increase the neuroexcitatory activities of Tramadol.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Triprolidine.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Tramadol.Approved
TropisetronTropisetron may decrease the analgesic activities of Tramadol.Investigational
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Tramadol.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Tramadol.Approved
Uc1010The risk or severity of adverse effects can be increased when Tramadol is combined with Uc1010.Investigational
UlaritideThe risk or severity of adverse effects can be increased when Tramadol is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Tramadol.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Tramadol is combined with Valproic Acid.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Tramadol.Approved
VenlafaxineVenlafaxine may increase the neuroexcitatory activities of Tramadol.Approved
VerapamilThe metabolism of Tramadol can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Tramadol is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Vilazodone.Approved
VoriconazoleThe serum concentration of Tramadol can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Tramadol is combined with Vortioxetine.Approved
WarfarinTramadol may increase the anticoagulant activities of Warfarin.Approved
XylazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Tramadol is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Tramadol is combined with Ziconotide.Approved
ZimelidineZimelidine may increase the neuroexcitatory activities of Tramadol.Withdrawn
ZiprasidoneThe therapeutic efficacy of Tramadol can be decreased when used in combination with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Zolmitriptan.Approved, Investigational
ZolpidemTramadol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Tramadol is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Tramadol is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Tramadol is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Tramadol is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Oral administration of tramadol hydrochloride with food does not significantly affect its rate or extent of absorption, therefore, tramadol hydrochloride can be administered without regard to food.
References
Synthesis Reference

Wolfgang Reimann, “Combination preparation containing tramadol and a calcium channel antagonist.” U.S. Patent US5929122, issued March, 1993.

US5929122
General References
  1. Dayer P, Desmeules J, Collart L: [Pharmacology of tramadol]. Drugs. 1997;53 Suppl 2:18-24. [PubMed:9190321 ]
  2. Harati Y, Gooch C, Swenson M, Edelman S, Greene D, Raskin P, Donofrio P, Cornblath D, Sachdeo R, Siu CO, Kamin M: Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998 Jun;50(6):1842-6. [PubMed:9633738 ]
  3. Harati Y, Gooch C, Swenson M, Edelman SV, Greene D, Raskin P, Donofrio P, Cornblath D, Olson WH, Kamin M: Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications. 2000 Mar-Apr;14(2):65-70. [PubMed:10959067 ]
  4. Gobel H, Stadler T: [Treatment of post-herpes zoster pain with tramadol. Results of an open pilot study versus clomipramine with or without levomepromazine]. Drugs. 1997;53 Suppl 2:34-9. [PubMed:9190323 ]
  5. Boureau F, Legallicier P, Kabir-Ahmadi M: Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain. 2003 Jul;104(1-2):323-31. [PubMed:12855342 ]
External Links
ATC CodesN02AX52N02AX02
AHFS Codes
  • 28:08.08
PDB EntriesNot Available
FDA labelDownload (408 KB)
MSDSDownload (74.7 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9924
Blood Brain Barrier+0.9382
Caco-2 permeable+0.8866
P-glycoprotein substrateSubstrate0.6283
P-glycoprotein inhibitor IInhibitor0.7807
P-glycoprotein inhibitor IIInhibitor0.9589
Renal organic cation transporterNon-inhibitor0.6398
CYP450 2C9 substrateNon-substrate0.7678
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7726
CYP450 1A2 substrateNon-inhibitor0.7136
CYP450 2C9 inhibitorNon-inhibitor0.704
CYP450 2D6 inhibitorInhibitor0.6566
CYP450 2C19 inhibitorNon-inhibitor0.6841
CYP450 3A4 inhibitorNon-inhibitor0.6256
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7832
Ames testNon AMES toxic0.7899
CarcinogenicityNon-carcinogens0.6663
BiodegradationNot ready biodegradable0.9975
Rat acute toxicity3.0316 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6136
hERG inhibition (predictor II)Inhibitor0.7098
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Cipher pharmaceuticals inc
  • Purdue pharma products lp
  • Par pharmaceutical
  • Biovail laboratories international srl
  • Victory pharma inc
  • Actavis elizabeth llc
  • Alphapharm party ltd
  • Amneal pharmaceuticals llc
  • Apotex inc
  • Asta medica inc
  • Caraco pharmaceutical laboratories ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mallinckrodt inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Northstar healthcare holdings ltd
  • Pliva inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories
  • Ortho mcneil janssen pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Capsule, extended releaseOral100 mg/1
Capsule, extended releaseOral200 mg/1
Capsule, extended releaseOral300 mg/1
Capsule, extended releaseOral100 mg
Capsule, extended releaseOral200 mg
Capsule, extended releaseOral300 mg
KitOral
CapsuleOral150 mg/1
Capsule, coated, extended releaseOral150 mg/1
Capsule, extended releaseOral150 mg/1
TabletOral50 mg/50mg
TabletOral50 mg/1
Tablet, coatedOral50 mg/1
Tablet, extended releaseOral100 mg/1
Tablet, extended releaseOral200 mg/1
Tablet, extended releaseOral300 mg/1
Tablet, film coatedOral50 mg/1
Tablet, coatedOral
Tablet, film coatedOral
CapsuleOral100 mg/1
CapsuleOral200 mg/1
CapsuleOral300 mg/1
Tablet, film coated, extended releaseOral100 mg/1
Tablet, film coated, extended releaseOral200 mg/1
Tablet, film coated, extended releaseOral300 mg/1
Kit
Tablet, extended releaseOral100 mg
TabletOral
TabletOral50 mg
Tablet, coatedOral50 mg/201
TabletOral100 mg/1
Tablet, extended releaseOral150 mg
Tablet, extended releaseOral200 mg
Tablet, extended releaseOral300 mg
Tablet, extended releaseOral400 mg
Tablet, extended releaseOral75 mg
Prices
Unit descriptionCostUnit
Tramadol hcl powder29.08USD g
Ultram ER 300 mg 24 Hour tablet10.66USD tablet
Ultram er 300 mg tablet10.25USD tablet
Ultram ER 200 mg 24 Hour tablet7.64USD tablet
Ultram er 200 mg tablet7.35USD tablet
TraMADol HCl 200 mg 24 Hour tablet6.25USD tablet
Ultram ER 100 mg 24 Hour tablet4.62USD tablet
Ultram er 100 mg tablet4.44USD tablet
TraMADol HCl 100 mg 24 Hour tablet3.78USD tablet
Ultram 50 mg tablet1.99USD tablet
Tramadol-Acetaminophen 37.5-325 mg tablet1.07USD tablet
Tramadol hcl 50 mg tablet0.7USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2123160 No2003-04-292014-05-09Canada
CA2476201 No2009-09-012023-02-21Canada
US5464632 No1993-03-222013-03-22Us
US6106861 No1997-12-052017-12-05Us
US6339105 Yes2000-04-122020-04-12Us
US6607748 No2000-06-292020-06-29Us
US7858118 No2002-04-112022-04-11Us
US7988998 No2003-10-272023-10-27Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point180-181 °CNot Available
water solubilitySoluble Not Available
logP2.4FDA label
pKa9.41FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.75 mg/mLALOGPS
logP2.71ALOGPS
logP2.45ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)13.8ChemAxon
pKa (Strongest Basic)9.23ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area32.7 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity78.27 m3·mol-1ChemAxon
Polarizability30.45 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4i-9010000000-ffea37e400f0860f2e7fView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenol ethers
Direct ParentAnisoles
Alternative Parents
Substituents
  • Methoxybenzene
  • Anisole
  • Aralkylamine
  • Cyclohexanol
  • Alkyl aryl ether
  • Tertiary alcohol
  • Cyclic alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
  • 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol (CHEBI:75725 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Gillen C, Haurand M, Kobelt DJ, Wnendt S: Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol. 2000 Aug;362(2):116-21. [PubMed:10961373 ]
  2. Potschka H, Friderichs E, Loscher W: Anticonvulsant and proconvulsant effects of tramadol, its enantiomers and its M1 metabolite in the rat kindling model of epilepsy. Br J Pharmacol. 2000 Sep;131(2):203-12. [PubMed:10991912 ]
  3. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL: Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther. 1992 Jan;260(1):275-85. [PubMed:1309873 ]
  4. Grond S, Sablotzki A: Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923. [PubMed:15509185 ]
  5. Ide S, Minami M, Ishihara K, Uhl GR, Sora I, Ikeda K: Mu opioid receptor-dependent and independent components in effects of tramadol. Neuropharmacology. 2006 Sep;51(3):651-8. Epub 2006 Jun 21. [PubMed:16793069 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Minami K, Uezono Y, Ueta Y: Pharmacological aspects of the effects of tramadol on G-protein coupled receptors. J Pharmacol Sci. 2007 Mar;103(3):253-60. [PubMed:17380034 ]
  8. Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B: Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung. 1996 Nov;46(11):1029-36. [PubMed:8955860 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Sagata K, Minami K, Yanagihara N, Shiraishi M, Toyohira Y, Ueno S, Shigematsu A: Tramadol inhibits norepinephrine transporter function at desipramine-binding sites in cultured bovine adrenal medullary cells. Anesth Analg. 2002 Apr;94(4):901-6, table of contents. [PubMed:11916794 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Berrocoso E, Mico JA: Cooperative opioid and serotonergic mechanisms generate superior antidepressant-like effects in a mice model of depression. Int J Neuropsychopharmacol. 2009 Sep;12(8):1033-44. doi: 10.1017/S1461145709000236. Epub 2009 Apr 3. [PubMed:19341511 ]
  4. Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B: Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung. 1996 Nov;46(11):1029-36. [PubMed:8955860 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Barann M, Urban B, Stamer U, Dorner Z, Bonisch H, Bruss M: Effects of tramadol and O-demethyl-tramadol on human 5-HT reuptake carriers and human 5-HT3A receptors: a possible mechanism for tramadol-induced early emesis. Eur J Pharmacol. 2006 Feb 15;531(1-3):54-8. Epub 2006 Jan 19. [PubMed:16427041 ]
  2. Driessen B, Reimann W: Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxytryptamine in the rat brain in vitro. Br J Pharmacol. 1992 Jan;105(1):147-51. [PubMed:1596676 ]
  3. Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B: Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung. 1996 Nov;46(11):1029-36. [PubMed:8955860 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Ogata J, Minami K, Uezono Y, Okamoto T, Shiraishi M, Shigematsu A, Ueta Y: The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents. [PubMed:15105221 ]
  2. Horishita T, Minami K, Uezono Y, Shiraishi M, Ogata J, Okamoto T, Shigematsu A: The tramadol metabolite, O-desmethyl tramadol, inhibits 5-hydroxytryptamine type 2C receptors expressed in Xenopus Oocytes. Pharmacology. 2006;77(2):93-9. Epub 2006 May 5. [PubMed:16679816 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Sun HL, Zheng JW, Wang K, Liu RK, Liang JH: Tramadol reduces the 5-HTP-induced head-twitch response in mice via the activation of mu and kappa opioid receptors. Life Sci. 2003 Jan 31;72(11):1221-30. [PubMed:12570923 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Wentland MP, Lou R, Lu Q, Bu Y, VanAlstine MA, Cohen DJ, Bidlack JM: Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. doi: 10.1016/j.bmcl.2008.10.134. Epub 2008 Nov 7. [PubMed:19027293 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein phosphatase 2a binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May play a role in the development of dendritic spines. May play a role in PPP2CB-NMDAR mediated signaling mechanism (By similarity).
Gene Name:
GRIN3A
Uniprot ID:
Q8TCU5
Molecular Weight:
125464.07 Da
References
  1. Hara K, Minami K, Sata T: The effects of tramadol and its metabolite on glycine, gamma-aminobutyric acidA, and N-methyl-D-aspartate receptors expressed in Xenopus oocytes. Anesth Analg. 2005 May;100(5):1400-5, table of contents. [PubMed:15845694 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Not Available
Specific Function:
Not Available
Gene Name:
CHRNA7
Uniprot ID:
Q693P7
Molecular Weight:
2987.635 Da
References
  1. Shiraishi M, Minami K, Uezono Y, Yanagihara N, Shigematsu A, Shibuya I: Inhibitory effects of tramadol on nicotinic acetylcholine receptors in adrenal chromaffin cells and in Xenopus oocytes expressing alpha 7 receptors. Br J Pharmacol. 2002 May;136(2):207-16. [PubMed:12010769 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Shiraishi M, Minami K, Uezono Y, Yanagihara N, Shigematsu A: Inhibition by tramadol of muscarinic receptor-induced responses in cultured adrenal medullary cells and in Xenopus laevis oocytes expressing cloned M1 receptors. J Pharmacol Exp Ther. 2001 Oct;299(1):255-60. [PubMed:11561087 ]
  2. Shiga Y, Minami K, Shiraishi M, Uezono Y, Murasaki O, Kaibara M, Shigematsu A: The inhibitory effects of tramadol on muscarinic receptor-induced responses in Xenopus oocytes expressing cloned M(3) receptors. Anesth Analg. 2002 Nov;95(5):1269-73, table of contents. [PubMed:12401609 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:11